IL155585A0 - Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain - Google Patents

Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain

Info

Publication number
IL155585A0
IL155585A0 IL15558502A IL15558502A IL155585A0 IL 155585 A0 IL155585 A0 IL 155585A0 IL 15558502 A IL15558502 A IL 15558502A IL 15558502 A IL15558502 A IL 15558502A IL 155585 A0 IL155585 A0 IL 155585A0
Authority
IL
Israel
Prior art keywords
chronic
compound
different types
novel use
peptide class
Prior art date
Application number
IL15558502A
Other languages
English (en)
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8176866&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL155585(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Publication of IL155585A0 publication Critical patent/IL155585A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL15558502A 2001-03-21 2002-03-19 Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain IL155585A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01107026A EP1243263B1 (en) 2001-03-21 2001-03-21 Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain
PCT/EP2002/003032 WO2002074297A1 (en) 2001-03-21 2002-03-19 Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain

Publications (1)

Publication Number Publication Date
IL155585A0 true IL155585A0 (en) 2003-11-23

Family

ID=8176866

Family Applications (3)

Application Number Title Priority Date Filing Date
IL15558502A IL155585A0 (en) 2001-03-21 2002-03-19 Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain
IL155585A IL155585A (en) 2001-03-21 2003-04-27 Use of the compound (r) - 2 - acetamido - n - benzyl - 3 - methoxypropionamide for the preparation of a pharmaceutical composition for treating allodynia as a major and unique pain symptom independent of the nature of the underlying disease or chronic or phantom pain
IL202688A IL202688A0 (en) 2001-03-21 2009-12-10 Novel use of a compound for treating diabetic neuropathic pain

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL155585A IL155585A (en) 2001-03-21 2003-04-27 Use of the compound (r) - 2 - acetamido - n - benzyl - 3 - methoxypropionamide for the preparation of a pharmaceutical composition for treating allodynia as a major and unique pain symptom independent of the nature of the underlying disease or chronic or phantom pain
IL202688A IL202688A0 (en) 2001-03-21 2009-12-10 Novel use of a compound for treating diabetic neuropathic pain

Country Status (26)

Country Link
US (3) US7875652B2 (es)
EP (3) EP1243263B1 (es)
JP (1) JP4154237B2 (es)
KR (1) KR100557852B1 (es)
CN (1) CN100522149C (es)
AT (3) ATE228358T1 (es)
AU (1) AU2002257680B2 (es)
BR (1) BR0208141A (es)
CA (1) CA2430470C (es)
CZ (1) CZ20032798A3 (es)
DE (2) DE60100055T2 (es)
DK (1) DK1243263T3 (es)
EA (1) EA007600B1 (es)
ES (3) ES2185606T3 (es)
HK (1) HK1048763B (es)
HU (1) HUP0303983A3 (es)
IL (3) IL155585A0 (es)
MX (1) MXPA03006438A (es)
NO (1) NO20033918L (es)
PL (1) PL368408A1 (es)
PT (1) PT1243263E (es)
SI (1) SI21169B (es)
SK (1) SK287714B6 (es)
UA (1) UA73854C2 (es)
WO (1) WO2002074297A1 (es)
ZA (1) ZA200303319B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1243262T3 (da) 2001-03-20 2006-10-02 Sanol Arznei Schwarz Gmbh Hidtil ukendt anvendelse af en peptidklasse af forbindelser til behandling af ikke-neuropatiske, inflammatoriske smerter
ATE228358T1 (de) * 2001-03-21 2002-12-15 Sanol Arznei Schwarz Gmbh Neue verwendung einer klasse von peptidverbindungen zur behandlung von allodynie oder andere arten von chronischen oder phantomschmerzen
KR20060111524A (ko) * 2003-12-02 2006-10-27 쉬바르츠파르마에이지 펩타이드 화합물들의 중추 신경병증성 통증 치료를 위한신규한 용도
EP1537862A1 (en) * 2003-12-02 2005-06-08 Schwarz Pharma Ag Novel use of peptide compounds for treating central neuropathic pain
EP1579858A1 (en) * 2004-03-26 2005-09-28 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in painful diabetic neuropathy
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
CA2562937A1 (en) * 2004-04-16 2005-10-27 Schwarz Pharma Ag Use of peptidic compounds for the prophylaxis and treatment of chronic headache
EP1604654A1 (en) * 2004-05-18 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating dyskinesia
EP1604656A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
EP1604655A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
US7427601B2 (en) * 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
WO2006021412A2 (en) * 2004-08-27 2006-03-02 Schwarz Pharma Ag Use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain
EP1629839A1 (en) * 2004-08-27 2006-03-01 Schwarz Pharma Ag Use of peptide compounds for treating bone cancer pain, chemotherapy- and nucleoside-induced pain
EP1642889A1 (en) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
CA2595330A1 (en) 2005-01-28 2006-08-03 Schwarz Pharma Ag Spm 927 for add-on therapy of schizophrenia
EP1754476A1 (en) 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
WO2007070252A2 (en) * 2005-11-30 2007-06-21 The University Of North Carolina At Chapel Hill Identification of genetic polymorphic variants associated with somatosensory disorders and methods of using the same
US7902401B2 (en) 2006-12-14 2011-03-08 Nps Pharmaceuticals, Inc. Fluorinated compounds
CN101466390B (zh) 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
EP1920780A1 (en) * 2006-10-12 2008-05-14 Schwarz Pharma Ag Peptide compounds for the treatment of hyperexcitability disorders
EP1873527A1 (en) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
EP2037965B1 (en) 2006-06-15 2017-08-30 UCB Pharma GmbH Pharmaceutical composition with synergistic anticonvulsant effect
CA2672494A1 (en) 2006-12-14 2008-06-19 Nps Pharmaceuticals, Inc. Use of d-serine derivatives for the treatment of anxiety disorders
MD3310G2 (ro) * 2006-12-27 2008-02-29 Ион МЕРЕУЦЭ Metodă de tratament al durerilor fantome
WO2009053070A1 (en) * 2007-10-23 2009-04-30 Schwarz Pharma Ag Compounds for treating demyelination conditions
EP2509939A4 (en) 2009-09-23 2013-09-18 Univ North Carolina NOVEL N-BENZYLAMIDE SUBSTITUTED DERIVATIVES OF 2- (ACYLAMIDO) ACETIC ACID AND 2- (ACYLAMIDO) PROPIONIC ACIDS: POWERFUL NEUROLOGIC AGENTS
EP2468261A1 (en) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide
EP2645997B1 (en) 2010-12-02 2022-08-10 UCB Pharma GmbH Once daily formulation of lacosamide
GB201200525D0 (en) * 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
KR20220147075A (ko) 2020-02-26 2022-11-02 에이지씨 가부시키가이샤 함불소 중합체, 막, 막의 제조 방법 및 유기 광전자 소자

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2937698A1 (de) * 1979-09-18 1981-04-02 A. Nattermann & Cie GmbH, 5000 Köln N-propionylsarcosinanilide, deren herstellungsverfahren und arzneimittel auf deren basis
FR2480747A1 (fr) * 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
US4533657A (en) * 1981-07-24 1985-08-06 Sterling Drug Inc. Analgesic dipeptide amides and method of use and composition thereof
FR2518088B1 (fr) * 1981-12-16 1987-11-27 Roques Bernard Nouveaux derives d'aminoacides, et leur application therapeutique
US4510082A (en) * 1983-03-07 1985-04-09 Eli Lilly And Company Pharmacologically active peptides
JPH0680079B2 (ja) * 1984-11-09 1994-10-12 エーザイ株式会社 ポリペプチド
US5654301A (en) 1985-02-15 1997-08-05 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5378729A (en) * 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
GB9103454D0 (en) 1991-02-19 1991-04-03 Pfizer Ltd Therapeutic agents
US5656267A (en) * 1991-08-22 1997-08-12 Sagen; Jacqueline Implantable cells that alleviate chronic pain in humans
TW217417B (es) 1991-12-04 1993-12-11 Manyu Seiyaku Kk
US5585358A (en) 1993-07-06 1996-12-17 Yissum Research Development Corporation Of The Hebrew University Of Jerusalem Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents
GB9504854D0 (en) * 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
US5536853A (en) * 1994-04-11 1996-07-16 Chiron Corporation Opiate receptor ligands
MY113062A (en) 1994-05-10 2001-11-30 The Wellcome Foundation Ltd Amide derivatives and their therapeutic use
US5508266A (en) * 1994-06-22 1996-04-16 Ciba-Geigy Corporation Gem-disubstituted amino acid derivatives
ES2133807T3 (es) * 1994-10-05 1999-09-16 Darwin Discovery Ltd Compuestos de peptidilo y su uso terapeutico como inhibidores de metaloproteasas.
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
US5780589A (en) * 1994-11-30 1998-07-14 The United States Of America As Represented By The Department Of Health And Human Services Ultraselective opioidmimetic peptides and pharmacological and therapeutic uses thereof
US5651301A (en) * 1994-12-13 1997-07-29 Unipat Aktiengessellschaft Hydrostatic piston machines
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5849737A (en) * 1995-04-14 1998-12-15 The Regents Of The University Of California Compositions and methods for treating pain
WO1997003677A1 (en) * 1995-07-24 1997-02-06 Trustees Of Boston University Inhibition of nmda receptor activity by pregnenolone sulfate derivatives
TW450807B (en) * 1995-09-15 2001-08-21 Pfizer Pharmaceutical compositions for treating tinnitus comprising neuroprotective agents
US6114390A (en) * 1995-11-30 2000-09-05 Karl Thomae Gmbh Amino acid derivatives, pharmaceutical compositions containing these compounds and processes for preparing them
US6037324A (en) * 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
GB9601724D0 (en) * 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
US5773475A (en) * 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
DE19614533A1 (de) 1996-04-12 1997-10-16 Basf Ag Neue alpha-Hydroxysäurederivate, ihre Herstellung und Verwendung
DE19614542A1 (de) * 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DE19614534A1 (de) 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
US6277825B1 (en) * 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
BR9710536A (pt) * 1996-07-24 1999-08-17 Warner Lambert Co Isobutilgaba e seus derivados para o tratamento da dor
US6589994B1 (en) 1996-08-30 2003-07-08 Nps Pharmaceuticals, Inc. Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound
US6126939A (en) * 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
DE19636046A1 (de) 1996-09-05 1998-03-12 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten
US6038324A (en) * 1997-02-21 2000-03-14 Ambourn; Paul R. Automotive surround sound circuit background of the invention
US6071966A (en) * 1997-06-30 2000-06-06 Merz + Co. Gmbh & Co. 1-amino-alkylcyclohexane NMDA receptor antagonists
ATE320249T1 (de) 1997-07-08 2006-04-15 Ono Pharmaceutical Co Aminosäurederivate
US6737408B1 (en) * 1997-08-07 2004-05-18 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
AU7696098A (en) 1997-08-11 1999-03-01 Algos Pharmaceutical Corporation Substance p inhibitors in combination with nmda-blockers for treating pain
DE19743143A1 (de) 1997-09-30 1999-04-01 Knoll Ag Pharmazeutische Kombinationspräparate
NZ504316A (en) 1997-10-31 2002-12-20 Basf Ag Pyrimidine substituted carboxylic acid derivatives which have amido side-chains useful as endothelin receptor antagonists
US6492553B1 (en) * 1998-01-29 2002-12-10 Aventis Pharamaceuticals Inc. Methods for preparing N-[(aliphatic or aromatic)carbonyl)]-2-aminoaetamide compounds and for cyclizing such compounds
US6028102A (en) 1998-02-24 2000-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anticonvulsant drugs and pharmaceutical compositions thereof
US6673832B1 (en) 1998-05-04 2004-01-06 Gudarz Davar Methods for identifying compounds for treating pain
GB9812683D0 (en) * 1998-06-12 1998-08-12 Smithkline Beecham Plc Novel compounds
CN100424079C (zh) 1999-09-03 2008-10-08 埃科特莱茵药品有限公司 双磺胺
SE0001373D0 (sv) 2000-04-13 2000-04-13 Karolinska Innovations Ab NPY Y1 receptor agonists and antagonists
AU8830801A (en) 2000-08-17 2002-02-25 Teva Pharma Use of derivatives of valproic acid amides and 2-valproenic acid amides for the treatment or prevention of pain and/or headache disorders
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
DK1486205T3 (da) 2000-08-25 2008-02-18 Res Corp Technologies Inc Anvendelse af antikonvulsive aminosyrer til behandling af migræne
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
ATE397584T1 (de) 2000-11-21 2008-06-15 Ucb Pharma Sa N-alkylierte gaba verbindungen, verfahren zu deren herstellung und deren verwendung als arzneimittel
DK1243262T3 (da) 2001-03-20 2006-10-02 Sanol Arznei Schwarz Gmbh Hidtil ukendt anvendelse af en peptidklasse af forbindelser til behandling af ikke-neuropatiske, inflammatoriske smerter
ATE228358T1 (de) * 2001-03-21 2002-12-15 Sanol Arznei Schwarz Gmbh Neue verwendung einer klasse von peptidverbindungen zur behandlung von allodynie oder andere arten von chronischen oder phantomschmerzen
BR0207715A (pt) 2001-03-27 2004-03-23 Actelion Pharmaceuticals Ltd Compostos, composições farmacêuticas, e uso de um ou mais compostos
BR0209199A (pt) 2001-04-26 2006-02-07 Bristol Myers Squibb Co Controle de campactabilidade através de cristalização
ITMI20011308A1 (it) 2001-06-21 2002-12-21 Nicox Sa Farmaci per il dolore cronico
AU2003243180A1 (en) * 2002-05-17 2003-12-12 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
ATE361289T1 (de) 2002-08-05 2007-05-15 Lilly Co Eli Piperazinsubstituierte arylbenzodiazepine
AU2003276201A1 (en) 2002-11-11 2004-06-03 Bayer Healthcare Ag Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist
CA2544467C (en) 2002-11-18 2014-02-18 John M. Stewart Paralytic peptide for use in neuromuscular therapy
US7687080B2 (en) * 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
US6991764B2 (en) * 2002-12-13 2006-01-31 Dade Behring Inc. Method for replacing used reaction cuvettes in an automatic analyzer depending upon next scheduled assay
BR0317392A (pt) 2002-12-19 2005-12-20 Pharmacia Corp Formulação não-higroscópica incluindo uma droga higroscópica
US20040209960A1 (en) 2003-01-30 2004-10-21 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using sodium channell modulators
AU2004207009A1 (en) 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Use of sodium channel modulators for treating gastrointestinal tract disorders
US20040265375A1 (en) 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
US20040266743A1 (en) 2003-05-09 2004-12-30 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
US7307669B2 (en) * 2003-06-24 2007-12-11 Broadcom Corporation System, method, and apparatus for displaying streams with dynamically changing formats
US7320675B2 (en) * 2003-08-21 2008-01-22 Cardiac Pacemakers, Inc. Method and apparatus for modulating cellular metabolism during post-ischemia or heart failure
KR20060111524A (ko) 2003-12-02 2006-10-27 쉬바르츠파르마에이지 펩타이드 화합물들의 중추 신경병증성 통증 치료를 위한신규한 용도
EP1537862A1 (en) 2003-12-02 2005-06-08 Schwarz Pharma Ag Novel use of peptide compounds for treating central neuropathic pain
EP1541138A1 (en) 2003-12-05 2005-06-15 Schwarz Pharma Ag Novel use of peptide compounds for treating status epilepticus or related conditions
US20060009384A1 (en) 2003-12-05 2006-01-12 David Rudd Novel use of peptide compounds for treating status epilepticus or related conditions
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (en) 2004-03-26 2005-09-28 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in painful diabetic neuropathy
US20070042969A1 (en) 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
US20050227961A1 (en) * 2004-04-08 2005-10-13 Vela Pharmaceuticals, Inc. Compositions and methods for treatment of neuropathic pain, fibromyalgia and chronic fatigue syndrome
CA2562937A1 (en) 2004-04-16 2005-10-27 Schwarz Pharma Ag Use of peptidic compounds for the prophylaxis and treatment of chronic headache
EP1598428A1 (en) * 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
EP1604654A1 (en) * 2004-05-18 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating dyskinesia
EP1604655A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
EP1604656A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
US7427601B2 (en) * 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
WO2006021412A2 (en) * 2004-08-27 2006-03-02 Schwarz Pharma Ag Use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain
EP1642889A1 (en) 2004-10-02 2006-04-05 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
US20060252749A1 (en) 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
EP1688137A1 (en) 2005-01-28 2006-08-09 Schwarz Pharma Ag SPM 927 for add-on therapy of schizophrenia
EP1754476A1 (en) 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
US20070048372A1 (en) 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
EP1873527A1 (en) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
CN101466390B (zh) * 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
EP2037965B1 (en) * 2006-06-15 2017-08-30 UCB Pharma GmbH Pharmaceutical composition with synergistic anticonvulsant effect
JP4355003B2 (ja) * 2007-03-08 2009-10-28 本田技研工業株式会社 内燃機関の制御装置
WO2009053070A1 (en) * 2007-10-23 2009-04-30 Schwarz Pharma Ag Compounds for treating demyelination conditions
CN101841984A (zh) * 2009-03-19 2010-09-22 鸿富锦精密工业（深圳）有限公司 电子装置及其按键组件

Also Published As

Publication number Publication date
SK12902003A3 (sk) 2004-06-08
SK287714B6 (en) 2011-07-06
EP1383487A1 (en) 2004-01-28
EP2201943B1 (en) 2011-08-03
ATE490766T1 (de) 2010-12-15
ATE518532T1 (de) 2011-08-15
IL202688A0 (en) 2010-06-30
US7875652B2 (en) 2011-01-25
SI21169B (sl) 2011-06-30
PT1243263E (pt) 2003-03-31
JP2004524337A (ja) 2004-08-12
DE60238524D1 (de) 2011-01-20
IL155585A (en) 2010-12-30
EP2201943A1 (en) 2010-06-30
ZA200303319B (en) 2003-07-08
CA2430470A1 (en) 2002-09-26
JP4154237B2 (ja) 2008-09-24
AU2002257680B2 (en) 2006-12-14
BR0208141A (pt) 2004-03-02
EA007600B1 (ru) 2006-12-29
US20040220077A1 (en) 2004-11-04
NO20033918D0 (no) 2003-09-04
EP1243263A1 (en) 2002-09-25
ES2185606T3 (es) 2003-05-01
KR20030076604A (ko) 2003-09-26
DK1243263T3 (da) 2003-03-17
CN1498104A (zh) 2004-05-19
UA73854C2 (en) 2005-09-15
HUP0303983A3 (en) 2012-01-30
HK1048763B (zh) 2003-08-01
EP1243263B1 (en) 2002-11-27
ATE228358T1 (de) 2002-12-15
EA200300933A1 (ru) 2004-04-29
KR100557852B1 (ko) 2006-03-10
HK1048763A1 (en) 2003-04-17
MXPA03006438A (es) 2004-05-24
CZ20032798A3 (cs) 2007-06-20
CN100522149C (zh) 2009-08-05
NO20033918L (no) 2003-09-04
EP1383487B1 (en) 2010-12-08
ES2354417T3 (es) 2011-03-14
US20110082211A1 (en) 2011-04-07
CA2430470C (en) 2008-11-04
ES2368317T3 (es) 2011-11-16
PL368408A1 (en) 2005-03-21
HUP0303983A2 (hu) 2004-04-28
US20100099770A1 (en) 2010-04-22
DE60100055D1 (de) 2003-01-09
DE60100055T2 (de) 2003-07-24
SI21169A (sl) 2003-10-31
WO2002074297A1 (en) 2002-09-26

Similar Documents

Publication Publication Date Title
HK1048763A1 (en) Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain
IL175770A0 (en) Novel use of peptide compounds for treating central neuropathic pain
BG103264A (en) Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
EA200501744A1 (ru) Пептид (варианты), содержащая его композиция и лекарственный препарат для профилактики и лечения астеросклероза
GB0013407D0 (en) Forms of a chemical compound
IL128568A0 (en) Use of cyclooxygenase-2 inhibitors for the manufacture of a medicament for the treatment and prevention of neoplasia
IL175398A0 (en) Steroidal compounds and pharmaceutical compositions containing them for treating oxidative stress and inflammation
EP1390525B8 (en) Pyruvate-kinase as a novel target molecule
EP1273299A4 (en) MINOXIDIL PREPARATIONS
WO2002059143A3 (en) Therapeutic peptides for demyelinating conditions
EP1445253A4 (en) 4,4-DIFLUOR-1,2,3,4-TETRAHYDRO-5H-1-BENZAZEPINE DERIVATIVES AND THEIR SALTS
CA2264063A1 (en) Cryptophycin compounds
WO2003022844A3 (en) Synthesis of epothilones intermediates thereto and analogues thereof
WO2002083842A3 (en) Small molecule inhibitors of secretion of proteins encoded by are-mrnas
WO2001000784A3 (fr) COMPOSE PEPTIDIQUE DERIVE D'UNE ORF DECALEE DU GENE iCE
WO2001090139A3 (en) A ligand for enhancing oral and cns delivery of biological agents
EP1760087A4 (en) NEW PROTEIN COMPLEX AND USE OF THIS COMPLEX
WO2003011309A3 (de) Verwendung einer calciumhaltigen pharmazeutischen zusammensetzung zur behandlung von hypercholesterinämie
WO2003059394A3 (fr) Compositions pour la vectorisation d'oligonucleotides a travers la barriere hematoencephalique et leur utilisatin pour le traitement des maladies du systeme nerveux central